Table V.
Univariate analysis | Multivariate analysis | |||||||
---|---|---|---|---|---|---|---|---|
SNP | Outcome | mOS, months | Model | Log-rank P-value | HR (95% CI) | P-value | HR (95% CI)a | P-value |
KDR rs2034965 | OS | Dominant | 0.031 | 0.032 | 0.029 | |||
11.6 | GG | Reference | Reference | |||||
10.3 | AA+GA | 1.687 (1.039–2.738) | 0.034 | 1.978 (1.193–3.280) | 0.008 | |||
NRP1 rs2065364 | OS | Recessive | 0.037 | 0.039 | 0.105 | |||
17.8 | AA | Reference | Reference | |||||
11.0 | AG+GG | 2.367 (1.019–5.496) | 0.045 | 2.048 (0.847–4.952) | 0.112 | |||
KDR rs1870377 | OS | Dominant | 0.032 | 0.034 | 0.035 | |||
16.0 | TT | Reference | Reference | |||||
10.8 | AA+AT | 2.041 (1.042–3.999) | 0.038 | 2.264 (1.130–4.536) | 0.021 | |||
NRP1 rs2804495 | OS | Recessive | 0.029 | 0.031 | 0.084 | |||
8.8 | TT | Reference | Reference | |||||
12.0 | GT+GG | 1.710 (1.046–2.796) | 0.033 | 1.570 (0.924–2.667) | 0.095 |
Adjusted for age, gender, N stage, TNM stage and differentiation. CI, confidence interval; HR, hazard ratio; KDR, kinase insert domain receptor; NRP-1, neuropilin-1; OS, overall survival; mOS, median overall survival; SNP, single nucleotide polymorphism.